Experimental drug boosts treatment response for hard-to-treat ovarian cancer

The Medical News ·
Health & Medicine United Kingdom

Patients with advanced, hard-to-treat ovarian cancer have responded well to treatment with a drug called IACS-6274 when combined with the targeted therapy bevacizumab and paclitaxel chemotherapy.

Read original article on The Medical News →